Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gero logo — AI-driven drug discovery company focused on therapies target...

Gero

AI-driven drug discovery company focused on therapies targeting age-related diseases

Founded 2018 United States Palo Alto, United States 145 employees Series B Total: $25.20M AI, Biotechnology +2

General Information

Company Name Gero
Founded Year 2018
Location United States Palo Alto, United States
Employees 145
Industries AI, Biotechnology, Insurtech +1
Funding Stage Series B
Business Model B2B, Platform, SaaS
Revenue Model Licensing, Project Based, Performance Based
Offices as of Sep 2026
Palo Alto, United States Singapore, Singapore
Social

BounceWatch is an independent company data service, not affiliated with Gero. To contact Gero, visit gero.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Homepage Update

Significant changes detected on company website (58.9% content change).

Get alerts when Gero shows new signals

About Gero

Gero, founded in 2018, is an AI-driven drug discovery company focused on therapies targeting age-related diseases. The company is headquartered in the United States and operates at the intersection of AI, Biotechnology, Insurtech, and Pharmaceutical industries.

At its core, Gero aims to eliminate age-related diseases by leveraging AI to build clinically relevant disease phenotypes using real-world human data. By identifying diseases with shared biology, Gero is able to apply whole exome sequencing (WES) to discover novel targets that can be beneficial across multiple indications, enhancing drug discovery efficiency.

The company recently secured a $6.00M Series A investment, dated 01 October 2023, with backing from investors including VitaDAO, Melnichek Investments LTD, and Leo Lozner. This funding signifies confidence in Gero's innovative approach and its potential to revolutionize treatment paradigms in the pharmaceutical industry.

Taxonomy: AI Drug Discovery, Age-related Diseases, Preclinical Stage, Disease Phenotypes, Real-world Human Data, Genetic Study, Novel Target Discovery, Chronic Diseases, Longevity Research, Marker Identification, Drug Development, mHealth, Digital Health, Biological Age

Services & Products

Developing drugs targeting aging
AI models for disease progression
Collaborative drug discovery with pharma companies

Target Customers

Pharmaceutical companies Healthcare researchers Investors interested in biotechnology Aging and longevity research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $17.00M 1
Melnichek Investments LTD
Melnichek Investments LTD
01 Jun 2025
Series A $6.00M 3
VitaDAO Melnichek Investments LTD
VitaDAO, Melnichek Investments LTD +1
01 Oct 2023
Series A $2.20M 1
BUBA Ventures
BUBA Ventures
01 Aug 2020
Seed Undisclosed 1
BUBA Ventures
BUBA Ventures
01 May 2019

Gero Alternatives & Competitors

View All Alternatives
Gero vs
Samsara Therapeutics
Samsara Therapeutics United Kingdom

Treating Neurodegenerative Disease by Restoring Autophagy

Series A
12 employees
Biopharma, Biotechnology
Gero vs
LIPUM AB
LIPUM AB Sweden

We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases

Post-IPO Equity
15 employees
Biotechnology, Health Care
Gero vs
Insilico Medicine
Insilico Medicine United States

#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD

IPO
288 employees
AI, Biotechnology
View all alternatives

FAQ About Gero

AI-driven drug discovery company focused on therapies targeting age-related diseases
Gero was founded in 2018.
Gero is headquartered in Palo Alto, United States. As of Sep 2026, it also has offices in Singapore, Singapore.
Gero operates in AI, Biotechnology, Insurtech and Pharmaceutical. Its work centres on AI Drug Discovery, Age-related Diseases, Preclinical Stage and Disease Phenotypes. Its customers include Pharmaceutical companies, Healthcare researchers and Investors interested in biotechnology.
Gero has a B2B, Platform and SaaS business model. Its revenue comes from Licensing, Project Based and Performance Based.
Gero has approximately 145 employees.
Gero has completed 4 funding rounds, raising a total of $25.20M. The latest funding stage is Series B.
Gero offers: Developing drugs targeting aging, AI models for disease progression, Collaborative drug discovery with pharma companies.
Top alternatives and competitors to Gero include Samsara Therapeutics, LIPUM AB, Insilico Medicine, Standigm, Elixir Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gero and Samsara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Gero, https://bouncewatch.com/company/gero, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes